Abstract
Novel discoveries in molecular disease pathways within the cell, combined with increasing information regarding protein binding partners has lead to a new approach in drug discovery. There is interest in designing drugs to modulate protein-protein interactions as opposed to solely targeting the catalytic active site within a single enzyme or protein. There are many challenges in this new approach to drug discovery, particularly since the protein-protein interface has a larger surface area, can comprise a discontinuous epitope, and is more amorphous and less well defined than the typical drug design target, a small contained enzyme-binding pocket. Computational methods to predict modes of protein-protein interaction, as well as protein interface hot spots, have garnered significant interest, in order to facilitate the development of drugs to successfully disrupt and inhibit protein-protein interactions. This review summarizes some current methods available for computational protein-protein docking, as well as tabulating some examples of the successful design of antagonists and small molecule inhibitors for protein-protein interactions. Several of these drugs are now beginning to appear in the clinic.
Keywords: Protein-protein interactions, fragment-based ligand design, protein-protein inhibitors, computational drug design, structure-based ligand design, protein-interface hot-spots
Current Pharmaceutical Design
Title: Computational Drug Design Targeting Protein-Protein Interactions
Volume: 18 Issue: 9
Author(s): Rachelle J. Bienstock
Affiliation:
Keywords: Protein-protein interactions, fragment-based ligand design, protein-protein inhibitors, computational drug design, structure-based ligand design, protein-interface hot-spots
Abstract: Novel discoveries in molecular disease pathways within the cell, combined with increasing information regarding protein binding partners has lead to a new approach in drug discovery. There is interest in designing drugs to modulate protein-protein interactions as opposed to solely targeting the catalytic active site within a single enzyme or protein. There are many challenges in this new approach to drug discovery, particularly since the protein-protein interface has a larger surface area, can comprise a discontinuous epitope, and is more amorphous and less well defined than the typical drug design target, a small contained enzyme-binding pocket. Computational methods to predict modes of protein-protein interaction, as well as protein interface hot spots, have garnered significant interest, in order to facilitate the development of drugs to successfully disrupt and inhibit protein-protein interactions. This review summarizes some current methods available for computational protein-protein docking, as well as tabulating some examples of the successful design of antagonists and small molecule inhibitors for protein-protein interactions. Several of these drugs are now beginning to appear in the clinic.
Export Options
About this article
Cite this article as:
J. Bienstock Rachelle, Computational Drug Design Targeting Protein-Protein Interactions, Current Pharmaceutical Design 2012; 18 (9) . https://dx.doi.org/10.2174/138161212799436449
DOI https://dx.doi.org/10.2174/138161212799436449 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Enhanced Activity of pSTAT-3 Ser-727 in Functional Endothelial Cells Under Calcifying Conditions
Current Chemical Biology Amino Acid Transporter-Targeted Radiotracers for Molecular Imaging in Oncology
Current Medicinal Chemistry Current Concepts on the Management of Chordoma
Current Drug Therapy Stable Gastric Pentadecapeptide BPC 157-NO-system Relation
Current Pharmaceutical Design Metabolic Transformation and Mechanism of Action of Mononitroso Caffeidine- A New Interpretation
Endocrine, Metabolic & Immune Disorders - Drug Targets Nanostructured Therapeutic Systems of PUFAs for the Treatment of Glioblastoma Multiforme
Current Drug Metabolism Network Systems Underlying Traditional Chinese Medicine Syndrome and Herb Formula
Current Bioinformatics P2X Receptors and Inflammation
Current Medicinal Chemistry Three-Dimensional Ultrasound in Gynecology: Current Status and Future Perspectives
Current Women`s Health Reviews The Use of Chronobiotics in the Resynchronization of the Sleep/Wake Cycle. Therapeutical Application in the Early Phases of Alzheimer's Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Fluorescent Molecular Imaging: Technical Progress and Current Preclinical and Clinical Applications in Urogynecologic Diseases
Current Molecular Medicine Screening for Infectious Diseases During Pregnancy: Which Test and Which Situation
Current Women`s Health Reviews Synthesis of Purine Derivatives as Scaffolds for a Diversity of Biological Activities
Current Organic Chemistry Application of Metabolomics in Drug Discovery, Development and Theranostics
Current Metabolomics Local Activation and Systemic Dysregulation of T Lymphocytes in Sjögren’s Syndrome
Current Pharmaceutical Biotechnology Bacterial Zinc Proteases and their Inhibition
Current Enzyme Inhibition Insights on the Neuromodulatory Propensity of Selaginella (Sanjeevani) and its Potential Pharmacological Applications
CNS & Neurological Disorders - Drug Targets Development of Arene Ruthenium Antitumor Complexes
Mini-Reviews in Medicinal Chemistry Combining Oncolytic Virotherapy and Cytotoxic Therapies to Fight Cancer
Current Pharmaceutical Design High-Risk HPV/ErbB-2 Interaction on E-Cadherin/Catenin Regulation in Human Carcinogenesis
Current Pharmaceutical Design